SOCIAL MEDIA

ProfilePicture.png

Twitter

Oncology Times immunotherapy, NSCLC, ASCOrewind: 05/12/2021 14:30:13


#​Researchers have reported for the first time that an #immunotherapy agent has extended disease-free survival in patients with early-stage #NSCLC: https://t.co/MBUNg7MTqH #ASCOrewind


Read more

ProfilePicture.png

Twitter

OncLive SOSS lcsm: 05/12/2021 13:00:48


.@LealTiciana, of @WinshipAtEmory, discusses developments made in the treatment of patients with EGFR exon 20 insertion–mutant non–small cell lung cancer #lcsm


Read more

ProfilePicture.png

Twitter

OncLive SOSS lcsm: 05/12/2021 15:01:01


.@LealTiciana, of @WinshipAtEmory, discusses the evolution of treatment in EGFR exon 20 insertion–positive non–small cell lung cancer #lcsm


Read more

ProfilePicture.png

Twitter

OncLive.com lcsm, oncology: 05/12/2021 16:00:40


Findings showed that the median PFS with the novel sintilimab combination regimen was 6.9 months per IRRC assessment vs 4.3 months with chemotherapy alone. #lcsm #oncology https://t.co/GJLM5NUNnY


Read more